Curatis Holding AG (SWX:CURN)

Market Cap	113.93M +118.4%
Revenue (ttm)	10.80M +56.6%
Net Income	-1.42M
EPS	-0.28
Shares Out	5.16M
PE Ratio	n/a
Forward PE	1.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,325
Open	22.90
Previous Close	22.10
Day's Range	22.50 - 24.20
52-Week Range	10.05 - 27.90
Beta	-0.83
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 15, 2026

About Curatis Holding AG

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collage...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 9
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: CURN

Financial Performance

In 2025, Curatis Holding AG's revenue was 10.80 million, an increase of 56.61% compared to the previous year's 6.90 million. Losses were -1.42 million, -67.41% less than in 2024.